An index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.
Quick Links
As May 9, 2024 | Index Level | 3-Month | 6-Month | 1-Year | YTD |
Price Return | 1,519.4 | 9.8% | 28.5% | 28.5% | 19.6% |
Total Return | 1,596.4 | 10.6% | 29.7% | 30.7% | 20.6% |
Net Total Return | 1,578.4 | 10.4% | 29.4% | 30.2% | 20.3% |
Index Level | 1,519.4 |
---|---|
3-Month | 9.8% |
6-Month | 28.5% |
1-Year | 28.5% |
YTD | 19.6% |
Index Level | 1,596.4 |
---|---|
3-Month | 10.6% |
6-Month | 29.7% |
1-Year | 30.7% |
YTD | 20.6% |
Index Level | 1,578.4 |
---|---|
3-Month | 10.4% |
6-Month | 29.4% |
1-Year | 30.2% |
YTD | 20.3% |
As of May 9, 2024
Index Symbol (Price Return) | THINR |
Index Symbol (Total Return) | THINRT |
Index Symbol (Net Total Return) | THINRN |
Number of Constituents | 21 |
Market Capitalization | $2.59 Trillion |
Adjusted Market Capitalization | $2.42 Trillion |
Rebalancings | Quarterly |
Dividend Yield | 1.56% |
VettaFi's indexes are widely used by financial firms, industry stakeholders and professionals to support a variety of business functions. We offers a range of end-of-day and historical index data subscriptions.
Contact Us